Insulin Access in Diabetes Care

Why Is Insulin Still Hard To Access?

Insulin is not a new medicine, but it remains one of the clearest examples of how drug access depends on more than scientific discovery. The World Health Organization lists insulin as an essential medicine, and WHO diabetes data show that hundreds of millions of people now live with diabetes worldwide. For people with type 1 diabetes, insulin is not optional; for many with advanced type 2 diabetes, it becomes necessary when other therapies no longer control blood glucose adequately.

The barriers differ by setting. In some countries, insulin may be available but unaffordable at the pharmacy counter. In others, supply interruptions, lack of refrigeration, limited glucose-monitoring tools or shortages of trained clinicians make safe use harder. Even where newer analog insulins and connected devices are available, patients may ration doses if out-of-pocket costs are high, raising the risk of diabetic ketoacidosis, severe hyperglycemia and long-term vascular complications.

Can Biosimilar Insulins Improve Diabetes Treatment Access?

Biosimilar insulins are designed to be highly similar to already approved insulin products, with no clinically meaningful differences in safety, purity or potency when they meet regulatory standards. In the United States, the FDA has approved several follow-on or biosimilar insulin products, and some have received interchangeable status, which can make pharmacy substitution easier under applicable state rules.

However, biosimilars do not automatically solve access problems. Savings can be blunted by rebate structures, limited formulary placement or weak market competition. Public procurement, transparent pricing, patient-assistance programs and predictable insurance coverage may be just as important as the molecule itself. For clinicians, the practical goal is continuity: patients need an insulin they can obtain reliably, understand how to dose, and use alongside glucose monitoring and education.

What Should Patients Ask About Insulin Affordability?

Patients struggling to pay for insulin should not reduce or skip doses without medical advice. Dose rationing can quickly become dangerous, especially for people with type 1 diabetes. A clinician or pharmacist can review whether a lower-cost human insulin, a biosimilar insulin, a different pen or vial option, or a manufacturer or community assistance program is appropriate.

The safest access strategy is individualized. Some patients benefit from analog insulins because of lower hypoglycemia risk or easier timing; others may do well with less expensive human insulin when dosing, meals and monitoring are carefully aligned. Health systems can improve outcomes by pairing affordable insulin with diabetes education, glucose-monitoring support and clear sick-day instructions.